Core Laboratories (CLB) Given a $115.00 Price Target by Morgan Stanley Analysts
Core Laboratories (NYSE:CLB) received a $115.00 price target from analysts at Morgan Stanley in a research note issued to investors on Thursday. The firm currently has a “hold” rating on the oil and gas company’s stock. Morgan Stanley’s target price would indicate a potential upside of 7.23% from the company’s current price.
A number of other equities research analysts have also issued reports on the stock. Piper Jaffray Companies set a $95.00 price target on shares of Core Laboratories and gave the stock a “hold” rating in a report on Friday, October 5th. Edward Jones initiated coverage on shares of Core Laboratories in a report on Tuesday, September 4th. They issued a “buy” rating on the stock. JPMorgan Chase & Co. raised their price target on shares of Core Laboratories from $118.00 to $121.00 and gave the stock an “overweight” rating in a report on Monday, September 17th. Citigroup set a $116.00 price target on shares of Core Laboratories and gave the stock a “hold” rating in a report on Friday, September 14th. Finally, Stifel Nicolaus began coverage on shares of Core Laboratories in a report on Monday, September 10th. They issued a “hold” rating and a $117.00 price target on the stock. Two investment analysts have rated the stock with a sell rating, nine have issued a hold rating and six have given a buy rating to the company. Core Laboratories currently has an average rating of “Hold” and a consensus price target of $115.15.
Shares of Core Laboratories stock opened at $107.25 on Thursday. The firm has a market capitalization of $5.12 billion, a price-to-earnings ratio of 53.63, a PEG ratio of 3.96 and a beta of 1.46. Core Laboratories has a 12-month low of $87.66 and a 12-month high of $130.34. The company has a debt-to-equity ratio of 1.53, a quick ratio of 1.85 and a current ratio of 2.24.
Several institutional investors and hedge funds have recently made changes to their positions in the company. Personal Capital Advisors Corp bought a new stake in shares of Core Laboratories during the 3rd quarter valued at about $375,000. Douglas Lane & Associates LLC boosted its stake in shares of Core Laboratories by 33.7% during the 3rd quarter. Douglas Lane & Associates LLC now owns 28,562 shares of the oil and gas company’s stock valued at $3,308,000 after purchasing an additional 7,197 shares in the last quarter. Royal London Asset Management Ltd. bought a new stake in shares of Core Laboratories during the 2nd quarter valued at about $2,166,000. Northern Trust Corp boosted its stake in shares of Core Laboratories by 2.0% during the 2nd quarter. Northern Trust Corp now owns 484,007 shares of the oil and gas company’s stock valued at $61,086,000 after purchasing an additional 9,341 shares in the last quarter. Finally, WCM Investment Management CA boosted its stake in shares of Core Laboratories by 5.0% during the 2nd quarter. WCM Investment Management CA now owns 5,285,156 shares of the oil and gas company’s stock valued at $667,040,000 after purchasing an additional 249,329 shares in the last quarter.
About Core Laboratories
Core Laboratories N.V. provides reservoir description, and production enhancement services and products to the oil and gas industry in the United States, Canada, and internationally. It operates in two segments, Reservoir Description and Production Enhancement segments. The Reservoir Description segment comprises the characterization of petroleum reservoir rock, fluid, and gas samples to enhance production and improve recovery of oil and gas from its clients' reservoirs.
Read More: Discover Your Risk Tolerance
Receive News & Ratings for Core Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Core Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.